Your browser doesn't support javascript.
loading
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
Dickinson, Michael J; Barba, Pere; Jäger, Ulrich; Shah, Nirav N; Blaise, Didier; Briones, Javier; Shune, Leyla; Boissel, Nicolas; Bondanza, Attilio; Mariconti, Luisa; Marchal, Anne-Laure; Quinn, David S; Yang, Jennifer; Price, Andrew; Sohoni, Akash; Treanor, Louise M; Orlando, Elena J; Mataraza, Jennifer; Davis, Jaclyn; Lu, Darlene; Zhu, Xu; Engels, Boris; Moutouh-de Parseval, Laure; Brogdon, Jennifer L; Moschetta, Michele; Flinn, Ian W.
Afiliación
  • Dickinson MJ; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Barba P; Hematology Department, Hospital Universitari Vall d'Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Jäger U; Clinical Division of Hematology and Hemostaseology, Department of Medicine I, and Comprehensive Cancer Center, Vienna General Hospital - Medical University of Vienna, Vienna, Austria.
  • Shah NN; Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Blaise D; Département d'Hématologie, Programme de Transplantation et de Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Institut Paoli Calmettes, Marseille, France.
  • Briones J; Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
  • Shune L; University of Kansas Medical Center, Kansas City, Kansas.
  • Boissel N; Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, APHP, Paris, France.
  • Bondanza A; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Mariconti L; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Marchal AL; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Quinn DS; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Yang J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Price A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Sohoni A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Treanor LM; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Orlando EJ; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Mataraza J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Davis J; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Lu D; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Zhu X; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Engels B; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Moutouh-de Parseval L; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Brogdon JL; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Moschetta M; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Flinn IW; Sarah Cannon Research Institute and Tennessee Oncology Center for Blood Cancers, Nashville, Tennessee.
Cancer Discov ; 13(9): 1982-1997, 2023 09 06.
Article en En | MEDLINE | ID: mdl-37249512
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Animals Idioma: En Revista: Cancer Discov Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Animals Idioma: En Revista: Cancer Discov Año: 2023 Tipo del documento: Article País de afiliación: Australia